

DAFTAR PUSTAKA

- Adams, A. 2005. RNA Therapeutic enter Clinical Trials, *The Scientist*, January 17
- Acquaah, 2004. Understanding Biotechnology, an Integrated and Cyber-Based Approach. New Jersey: PearsonPrentice Hall.
- Biju, S.S., Talegaonkar, S., Mishra, P.R., and Khar, R., K. 2006. Vesicular Systems:An Overview. *Indian Journal of Pharmaceutical Sciences*. 142-144.
- Brown, T. A. 2010. *Gene cloning and DNA analysis*. Blackwell Publishing, Oxford.
- Campbell, N.A., Reece, J.B., Urry, L.A., Cain, M.L., Wasserman, S.A., Jackson, R.B., Minorsky, P.V. (2011). *Campbell biology*.- 9th ed. Pearson. United States of America
- Casali, N. dan Preston, A. 2003. *E. coli plasmid vectors: methods and applications* Humana Press, New Jersey.
- Clark, D.P., 2005, *Molecular Biology: Understanding the Genetic Revolution*, SanDiego, CA: Elsevier Academic Press
- Doyle, A., Griffith, S .J . B., 2000, *Cell and Tissue Culture for Medical Research*, 49, John Willey and Sons, Ltd., New York.
- Holmes, B. 2003. Gene therapy may switch off Huntington's. *NewScientist.com* 10.35, 13 March 2003.
- Indrawan, M., Primack, R. B., Supriatna, J. 2007. *Biologi: Konservasi*. Jakarta: Yayasan Obor Indonesia
- Izadi, M., Abiri, M., Keramatipour, M., 2009,"Producing a Mammalian GFP. Jannah, R., Nidhal Unsun L. 2019. Konstruksi dan Kloning Plasmid PCDNA3.1 (+) dengan Subgenotip B# Hepatitis B CoreAntigen (*HBcAg*) Sebagai KandidatVaksin DNA Hepatitis B. "*Jurnal Penelitian dan Kajian Ilmiah Kesehatan*".5(2): 125-131.
- Kusumawati, A., Pranowo, D., Widada, J.S., 2002,"Construction of An EukaryotikpcDNA3.1(+)-Based Vector for The Expression of Jembrana Disease Virus gag-ca Subunit Gene 1", *J. Biotech*, Dec, hal. 578-583.
- Lokhande *etal*, (2011)."*HBV and HCV immunophatogenesis*", in mukolov SL,Viralhepatitis, selected issues ofphatogenesis and diagnostics intech open, Croatia.
- Nidhal L., N., Ishak, J., and Kusumawati A. 2019. Expression of gag-CA of Jembrana Disease Virus with Cationic Liposomes and Chitosan NanoparticleDelivery Systems as DNA Vaccines Candidates. *Tropical Life Sciences Research*. 30(3): 15-36. Doi: <https://doi.org/10.21315/tlsr2019.30.3.2>.
- Ranade & Hollinger, 2003. *Drug Deilvery System*. 2nd edition. CRC Press 1-14.
- Ren, J., Karna, S., Lee, H., Yoo, S.M. and Na, D., 2019. Artificial transformation methodologies for improving the efficiency of plasmid DNA transformation and simplifying its use. *Applied Microbiology and Biotechnology*, 103(23–24), 9205– 9215. <https://doi.org/10.1007/s00253-019-10173-x>
- Roberts, J.P. 2004. *Gene therapy's Fall and Rise (Again)*. *The Scientist* 18(18): 22-24



- Rolland D, Gauthier M, Dugua JM, Fournier C, Delpech L, Watelet B, *et al.* (2001) "Purification of recombinant HBc antigen expressed in *Escherichia coli* and *Pichia pastoris*: comparison of size-exclusion chromatography and Akbar SMF, Al-Mahtab M, Uddin MH, Khan SI. (2013) "HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection". *Hepatobiliary Pancreat Dis Int*, 12(4): 363-9. ultracentrifugation". *J Chromatogr B Biomed SciAppl* 2001; 753: 51-65.
- Sambrook, Fritsch, E. F., Maniatis, T. (1989) "*Molecular Cloning: a Laboratory Manual*". Cold Spring Harbor Laboratory Press. USA
- Sambrook, J., Russell, D.W., 2001, *Molecular Cloning: A Laboratory Manual* 3rd Ed, New York: Cold Spring Harbor Laboratory Press
- Sharp, P.M., Li, W.H., (1987) "*The Codon Adaptation Index—a Measure of Directional Synonymous Codon Usage Bias, and Its Potential Applications*", *Nucleic Acids Res*, 15, hal. 1281-1295
- Sato, Y., Kumazawa, N., Yoshikawa, K., dan Kurusu, Y. 2005. Transformation of *Escherichia coli* Mediated by Natural Phospholipids.
- Sezonov, G., Joseleau, D dan D'Ari, R. 2007. *Escherichia coli* Physiology in Luria-Bertani Broth. *Journal of Bacteriology*. (189)23: 8746–8749
- Soemohardjo S. Penatalaksanaan pengidap virus hepatitis B dan pencegahannya. Dalam: Buku Ajar Ilmu Penyakit Dalam Jilid 1. Jakarta: Balai Penerbit FKUI; 1996. hlm. 322-5
- Son, K. K. *et al.* (2000) 'Cationic liposome and plasmid DNA complexes formed in serum-free medium under optimum transfection condition are negatively charged', *Biochimica et Biophysica Acta - Biomembranes*, 1466(1–2), pp. 11–15. doi: 10.1016/S0005-2736(00)00176-0.
- Sudjadi. 2008. *Health Biotechnology*. Yogyakarta: Kanisius
- Taira, K., Kataoka, K., and T. Niidome, 2005. *Non-viral Gene Therapy Gene Design and Delivery*, Springer, Tokyo, Pp. 35-74.
- Tyle and Praveen. 1990. *Specialized Drug Delivery Systems Manufacturing and Production Technology*. New York: Marcel Dekker, Inc.
- Unsunnidhal, L., Ishak, J. & Kusumawati, A. (2019) *Expression of gag-CA Gene of Jembrana Disease Virus with Cationic Liposomes and Chitosan Nanoparticle Delivery Systems as DNA Vaccine Candidates*. *Tropical Life Sciences Research*. [Online] 30 (3), 15–36. Available from: doi: <https://doi.org/10.21315/tlsr2019.30.3.2>.
- Unsunnidhal, L., Wasito, R., Nugraha Setyawan, E.M., Warsani, Z., *et al.* (2021) *Potential of polylactic-co-glycolic acid (PLGA) for delivery Jembrana disease DNA vaccine Model (pEGFP-C1-tat)*. *Journal of Veterinary Science*. [Online] 2 (6), 1–15. Available from: doi: [10.4142/jvs.2021.22.e76](https://doi.org/10.4142/jvs.2021.22.e76)
- Vennison, S.J., 2009, *Laboratory manual for genetic engineering*, New Delhi: PHI Learning Pvt. L
- Waty Rahmah, Apon Zaenal Mustopa, Suharsono, Ratih Asmana Ningrum, Hidayah Murtiyaningsih (2017) "Soluble expression and purification of hepatitis B core antigen (HBcAg) subgenotype B3 in *Escherichia coli* using thioredoxin fusion tag", *Asian Pacific Journal of Tropical Disease*, 7(8): 496-501. DOI: 10.12980/apjtd.7.2017D7-58.



- Wang, G., Pan, L. and Zhang, Y. (2011) 'Approaches to improved targeting of DNA vaccines', Human Vaccines. Taylor & Francis, 7(12), pp. 1271–1281. doi: 10.4161/hv.7.12.17983.
- Widoyono MPH. Penyakit Tropis Epidemiologi, Penularan, Pencegahan & Pemberantasannya. penerbit erlangga Indonesia. Jakarta; 2011
- Winarti, L., Martien, R. and Siswindari (2011) 'Formulation of nanoparticles from short chain chitosan as gene delivery system and transfection against T47D cell line Formulasi Nanopartikel menggunakan kitosan rantai', Majalah Farmasi Indonesia, 22(3), pp. 204–211.
- Wolff JA, RW Malone, P Williams, W Chong, G Acsadi, A Jani, *et al.* 1990. Direct gene transfer into mouse muscle in vivo. Science. 247: 1465-1468.
- Wolff JA, JJ Ludtke, G Acsadi, P Williams, A Jani. 1992. Longterm persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Gen. 1: 363-369.
- World Health Organization. 2012. "Hepatitis" B. Geneva: World Health Organization; [Online] Available from: <http://www.who.int/mediacentre/factsheets/fs204/en>. [Accessed on 05th June, 2021].
- Xiaoling-li, Bhaskara, R.J., 2006, Design of Controlled Release Drug Delivery Systems, USA: McGraw-Hill CHEMICAL ENGINEERING Inc.